Grifols hit by 5% share drop after results miss expectations

Shares in Spanish drugmaker Grifols (GRF: MC) declined more than 5% by Friday afternoon versus two days earlier, after the company’s half-year earnings failed to meet market predictions.

The company, principally a producer of blood plasma-based products, has presented figures for the first half of 2016, which show that sales for the six months have totalled 1.95 billion euros ($2.17 billion), which is 2.7% higher than in the same period of 2015.

Grifols’ earnings before interest, taxes, amortization and depreciation (EBITDA) figure for 2016’s first half was 553.6 million euros, which is 1.8% below the 563.6 million euros expected by analysts and is 1.3% less than the EBITDA figure for the opening six months of 2015.